Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

被引：0
|
作者：
Fu, S. [1 ]
Liu, J. [1 ]
Fu, P. [2 ]
Li, H. [3 ]
Yang, X. [3 ]
Xie, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Jinan Zhangqiu Dist Peoples Hosp, Jinan, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR mutant NSCLC; Brain Metastasis; Aumolertinib combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-03
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 50 条
  • [21] Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
    Ceresoli, G. L.
    Zucali, P. A.
    Mencoboni, M.
    Botta, M.
    Grossi, F.
    Cortinovis, D.
    Zilembo, N.
    Ripa, C.
    Tiseo, M.
    Favaretto, A. G.
    Soto-Parra, H.
    De Vincenzo, F.
    Bruzzone, A.
    Lorenzi, E.
    Gianoncelli, L.
    Ercoli, B.
    Giordano, L.
    Santoro, A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (03) : 552 - 558
  • [22] Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
    Lin, C.
    Su, W.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S484 - S484
  • [23] Bevacizumab plus chemotherapy extends survival of patients with first-line nonsquamous NSCLC
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (04): : 473 - 473
  • [24] First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    Xiong, Yanjuan
    Wang, Lu
    Zhang, Weihong
    Meng, Yuan
    Wang, Yang
    Shen, Meng
    Zhou, Li
    Li, Runmei
    Lv, Yingge
    Wang, Shengguang
    Ren, Xiubao
    Liu, Liang
    BMC CANCER, 2024, 24 (01)
  • [25] EFFECTIVENESS OF BEVACIZUMAB IN PATIENTS WITH LUNG ADENOCARCINOMA TREATED WITH PEMETREXED / CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY
    Magallanes, Manuel E.
    Cruz, Angelica
    Zincer, Fernando P.
    Bautista, Yolanda
    Aceves, Isabel E.
    Velazco, Monica S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S579 - S579
  • [26] Bevacizumab in the first-line therapy of advanced NSCLC
    Hasenoehrl, Norbert
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2007, 157 (21-22) : 576 - 578
  • [27] Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
    Fang, S.
    Xu, T.
    Liu, N.
    Wang, X. Y.
    Cheng, W. W.
    Fang, H. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [28] Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Hensing, Thomas A.
    Rademaker, Alfred
    Hart, Eric M.
    Blum, Matthew G.
    Milton, Daniel T.
    Bonomi, Philip D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3284 - 3289
  • [29] Surgical Resection Improves the Survival of NSCLC Patients with Pleural Metastasis Treated with First-Line EGFR-TKIs
    Zhang, B.
    Xiao, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1051 - S1051
  • [30] First-Line Management of EGFR Mutant NSCLC
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1656 - S1656
12345